Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27016922
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Sclerostin Inhibition in the Management of Osteoporosis
#MMPMID27016922
Appelman-Dijkstra NM
; Papapoulos SE
Calcif Tissue Int
2016[Apr]; 98
(4
): 370-80
PMID27016922
show ga
The recognition of the importance of the Wnt-signaling pathway in bone metabolism
and studies of patients with rare skeletal disorders characterized by high bone
mass identified sclerostin as target for the development of new therapeutics for
osteoporosis. Findings in animals and humans with sclerostin deficiency as well
as results of preclinical and early clinical studies with sclerostin inhibitors
demonstrated a new treatment paradigm with a bone building agent for the
management of patients with osteoporosis, the antifracture efficacy, and
long-term tolerability of which remain to be established in on-going phase III
clinical studies. In this article we review the currently available preclinical
and clinical evidence supporting the use of sclerostin inhibitors in
osteoporosis.
free
free
free
